Sublingual immunotherapy for latex allergy: Tolerability and safety profile of rush build-up phase

Current Medical Research and Opinion

Volumn 24, Issue 4, 2008, Pages 1147-1154

  Nucera, E ^a   Schiavino, D ^a   Sabato, V ^a   Colagiovanni, A ^a   Pecora, V ^a   Rizzi, A ^a   Aruanno, A ^a   Milani, M ^b   Pollastrini, E ^a   Patriarca, Giampiero ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b ELI LILLY   (Italy)

Author keywords

Adverse events; Latex allergy; Specific immunotherapy; Sublingual desensitization

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; LATEX; STEROID;

ADOLESCENT; ADULT; AGE; ALLERGY; ANAPHYLACTIC SHOCK; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; ASTHMA; ATOPY; BRONCHUS OBSTRUCTION; CHILD; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FLUSHING; HEADACHE; HUMAN; IMMUNOTHERAPY; MALE; ORAL PRURITUS; PRICK TEST; RHINITIS; SEX DIFFERENCE; SIDE EFFECT; SKIN TEST; TONGUE SWELLING; URTICARIA;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOGLOBULIN E; LATEX; LATEX HYPERSENSITIVITY; MALE; MIDDLE AGED; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SKIN TESTS; TIME FACTORS;

EID: 42549092355     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X291903     Document Type: Article

References (16)

1. Bousquet J, Van Cauwen-berge P, editors. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S146-S150
2. Bousquet J, Lockey R, Malling HJ, editors. World Health Organization position paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Allergy 1998;53:S3-S4
3. Passalacqua G, Durham SR. Global Allergy and Asthma European Network. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007;119:881-91
4. Patriarca G, Nucera E, Pollastrini E, et al. Sublingual desensitization: a new approach to latex allergy problem. Anesth Analg 2002;95:956-60
5. Nettis E, Colanardi MC, Soccio AL, et al. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. Br J Dermatol 2007;156:674-81
6. Nucera E, Schiavino D, Pollastrini E, et al. Sublingual desensitization in children with congenital malformations and latex allergy. Pediatr Allergy Immunol 2006;17:606-12
7. Bernardini R, Campodonico P, Burastero S, et al. Sublingual immunotherapy with a latex extract in paediatric patients: a double-blind, placebo-controlled study. Curr Med Res Opin 2006;22:1515-22
8. Nucera E, Schiavino D, Buonomo A, et al. Latex rush desensitization. Allergy 2001;56:86-7
9. Suli C, Parziale M, Lorini M, et al. Prevalence and risk factors for latex allergy: a cross sectional study on health-care workers of an Italian hospital. J Investig Allergol Clin Immunol 2004;14:64-9
10. Latza U, Haamann F, Baur X. Effectiveness of a nationwide interdisciplinary preventive programme for latex allergy. Int Arch Occup Environ Health 2005;78:394-402
11. Acero S, Alvarez MJ, Garcia BE, et al. Occupational asthma from natural rubber latex. Specific inhalation challenge test and evolution. J Investig Allergol Clin Immunol 2003;13:155-61
12. Blanco C. Latex fruit syndrome. Curr Allergy Asthma Rep 2003;3:47-53
13. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006;61:1236-7
14. Malling HJ, Weeke B. EAACI position paper: immunotherapy. Allergy 1993;48:7-35
15. Sastre J, Fernandez-Nieto M, Rico P, et al. Specific immunotherapy with a standardized latex extract in allergic workers: a double-blind, placebo-controlled study. J Allergy Clin Immunol 2003;111:985-94
16. Sastre J, Raulf-Heimsoth, Rihs HP, et al. IgE reactivity to latex allergens among sensitized healthcare workers before and after immunotherapy with latex. Allergy 2006;61:206-10